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Background: Smoking is considered to be the single most important preventable risk factor for respiratory
symptoms. Estimating prevalence of respiratory symptoms is important since they most often precede a diagnosis
of an obstructive airway disease, which places a major burden on the society. The aim of this study was to estimate
prevalence trends of respiratory symptoms and asthma among Swedish adults, in relation to smoking habits. A
further aim was to estimate the proportion of respiratory symptom and asthma prevalence attributable to smoking.
Methods: Data from two large-scale cross-sectional surveys among adults performed in northern Sweden in 1996
and 2006 were analysed. Identical methods and the same questionnaire were used in both surveys. The association
between smoking, respiratory symptoms and asthma was analysed with multiple logistic regression analyses.
Changes in prevalence of respiratory symptoms and asthma from 1996 to 2006 were expressed as odds ratios.
Additionally, the population attributable risks of smoking were estimated.
Results: The prevalence of most respiratory symptoms decreased significantly from 1996 to 2006. Longstanding
cough decreased from 12.4 to 10.1%, sputum production from 19.0 to 15.0%, chronic productive cough from 7.3 to
6.2%, and recurrent wheeze from 13.4 to 12.0%. Any wheeze and asthmatic wheeze remained unchanged. This
parallels to a decrease in smoking from 27.4 to 19.1%. In contrast, physician-diagnosed asthma increased from 9.4
to 11.6%. The patterns were similar after correction for confounders. All respiratory symptoms were highly
associated with smoking, and the proportion of respiratory symptoms in the population attributed to smoking
(PAR) ranged from 9.8 to 25.5%. In 2006, PAR of smoking was highest for recurrent wheeze (20.6%).
Conclusions: In conclusion, we found that respiratory symptoms, in particular symptoms common in bronchitis,
decreased among adults in northern Sweden, parallel to a decrease in smoking from 1996 to 2006. In contrast, the
prevalence of physician-diagnosed asthma increased during the same time-period. Up to one fourth of the
respiratory symptom prevalence in the population was attributable to smoking.
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Tobacco consumption is one of the main risk factors of
premature death and disability worldwide [1]. The use of
tobacco is rising globally mainly because of an increasing
smoking prevalence in many low and middle income
countries [2]. The societal costs of diseases related to to-
bacco use are substantial; e.g. estimated to more than
€500 billion in 2009, which corresponds to 4.6% of the
Gross Domestic Product of the European Union [3]. In
2008, about one out of three adults in the world smoked
[4], and the overall pattern in the World Health Organ-
isation (WHO) European region was similar. In Sweden
however, the prevalence of smoking has decreased during
the last decades [5,6].
Smoking is considered to be the single most important
preventable risk factor for respiratory symptoms, chronic
bronchitis and chronic obstructive pulmonary disease
(COPD) [7]. The relationship between asthma and smok-
ing is unclear, and contradictory results have been found in
different studies. Smoking has been considered a risk factor
for incident asthma in some studies [8-10], while others
have found no association [11]. Some cross-sectional stud-
ies on asthma prevalence have found an association be-
tween ex-smoking or ever-smoking and asthma [6,12],
while others have found no such association [13,14].
Asthma, chronic bronchitis and COPD contribute a
major burden on the society in terms of disability, mor-
tality and costs [15-17]. The prevalence of asthma has
been increasing from the 1950s [18-21], however, recent
studies imply that the asthma increase might have
reached a plateau in several westernized countries
[6,22,23]. Worldwide, the burden of COPD is steadily in-
creasing [24]. Estimating prevalence of respiratory symp-
toms is important since symptoms most often precede a
diagnosis of an obstructive airway disease [7], and since
symptom prevalence less likely is biased by healthcare
practice or diagnostic activity compared to diagnoses of
obstructive airway diseases. Few recent studies among
adults have reported trends in prevalence of respiratory
symptoms and asthma.
Within the Obstructive Lung Disease in Northern
Sweden (OLIN) Studies, prevalence and incidence of ob-
structive airway diseases have been studied since 1985
[25]. The aim of the present study was to estimate preva-
lence trends of respiratory symptoms and asthma among
adults in relation to smoking habits by two large-scale
cross-sectional studies performed in 1996 and 2006. A fur-
ther aim was to estimate the proportion of respiratory
symptom and asthma prevalence attributable to smoking.
Methods
Study population
This study was performed in Norrbotten, the northern-
most county of Sweden. In 1996, a population-basedsample of 8,333 subjects in ages 20–69 years were sent a
postal questionnaire including questions about respira-
tory symptoms, diseases and smoking habits. The sample
was randomly selected from the Swedish population
register. After two reminders, 85% participated.
Correspondingly, a new random sample consisting
of 7,997 subjects in ages 20–69 years were invited
in 2006. The methodology and questionnaire were
identical with the 1996 survey and 77% participated
(Table 1). The total population in Norrbotten between
20–69 years of age was approximately 168,000 in 1996
and 159,000 in 2006.
Questionnaire
The questionnaire includes questions on respiratory
symptoms and diseases, demographic data, smoking and
other possible determinants of disease. It was developed
from the British Medical Research Council questionnaire
and has been used in several large-scale studies mainly
in Sweden, Finland and Estonia [6,9,22,25-28].
Definitions
Asthma variables
Physician-diagnosed asthma: Have you been diagnosed
as having asthma by a physician. Ever asthma: Do you
have, or have you ever had asthma. Asthma medication:
Do you use asthma medication (on a regular basis or
when needed).
Bronchitis variables
Longstanding cough: Have you had longstanding cough
during recent years. Sputum production: Do you usually
have phlegm when coughing, or do you have phlegm in
your chest that is difficult to bring up. Chronic product-
ive cough: Bringing up phlegm when coughing on most
days during periods of at least 3 months during at least
2 successive years.
Wheeze variables
Any wheeze: Have you at any time during the last
12 months had wheezing or whistling in your chest. Re-
current wheeze: Do you usually have wheezing or whist-
ling in your chest when breathing. Asthmatic wheeze:
Wheeze with breathlessness during the last 12 months
when you did not have a cold.
Other variables
Family history of asthma: Does any of your parents or
siblings have, or have had, asthma. Smokers reported
smoking during the 12 months preceding the survey,
while Ex-smokers reported having quit smoking at least
12 months prior to the study. Smokers answered a
question about the number of consumed cigarettes: <5
cigarettes per day, 5–14 cigarettes per day, or >14
Table 1 Study population, invited and participants by study year, age group and sex
Age group Sex
20-29y 30-39y 40-49y 50-59y 60-69y Women Men All
Study year 1996
Invited N 1619 1721 1895 1694 1404 3982 4351 8333
Participated n 1317 1429 1616 1490 1252 3471 3633 7104
% 81.3 83.0 85.3 88.0 89.2 87.2 83.5 85.3
Study year 2006
Invited N 1428 1514 1718 1820 1517 3843 4154 7997
Participated n 941 1080 1312 1510 1322 3135 3030 6165
% 65.9 71.3 76.4 83.0 87.1 81.6 72.9 77.1
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nor ex-smoking.
Ethical approval
The study was approved by the Regional Ethical Review
Board at Umeå University, Sweden.
Analysis
Statistical analyses were performed using the IBM SPSS
software (Version 20.0; SPSS Inc., Chicago IL, USA).
Differences in prevalence between groups were tested by
the chi-square test or Mantel-Haenszel test for trend
and differences in continuous variables were tested by a
two-tailed Student’s T-test. A p-value <0.05 was consid-
ered statistically significant. Multiple logistic regression
models were used in order to calculate Odds Ratios (OR:s)
with 95% confidence intervals (CI) for the simultaneous
effects of independent variables on different outcomes.
The independent variables in the logistic regression
models were; age, sex, smoking habits, family history of
asthma and year of study, where age was divided into 10-
year categories. The same model was also applied for each
study year separately (each survey).
The population attributable risk (PAR) in% of a certain
risk factor expresses the proportion of the prevalence of
a condition in the population which is attributable to
that risk factor. PAR of smoking was calculated each
year as: ((PT-P0)/PT)*100, where PT = Prevalence of a
symptom/disease among all and P0 = Prevalence of a
symptom/disease among non- and ex-smokers. Corre-
sponding 95% CI for PAR were calculated using the
Maximum Likelihood method [29].
PAR was also calculated based on Odds Ratios for
smoking (non- and ex-smoking as reference) from logis-
tic regression models adjusted for age, sex and family
history of asthma, and is then referred to as “adjusted
PAR”. The formula for adjusted PAR is as follows: ((OR-
1)/OR)*P*100, where P = Prevalence of smoking among
cases with the symptom/disease [30].Results
Participation
The participation rate was significantly higher in 1996
compared to 2006 in most age groups and among men
and women. In 1996, 7,104 adults (85%) participated
and in 2006, 6,165 (77%) participated. In both surveys,
the participation rates were higher among women com-
pared to men, and increased by age (Table 1).
Smoking habits
The prevalence of smoking decreased significantly from
27.4% in 1996 to 19.1% in 2006 (p < 0.001). The decrease
was significant in all age groups as well as among men
and women (Table 2). Additionally, the proportion of
smokers who smoked >14 cigarettes/day decreased among
both smoking women (from 21.5 to 17.9%, p = 0.073) and
men (from 35.2 to 26.0%, p = 0.001).
Smoking habits differed significantly (p < 0.001) between
age groups in both surveys, with smoking being most
common among subjects 40–59 year old (Table 2). In both
surveys, more women than men were smokers (p < 0.001).
Respiratory symptoms and asthma
The prevalence of most respiratory symptoms decreased
significantly from 1996 to 2006. Longstanding cough de-
creased from 12.4 to 10.1%, sputum production from
19.0 to 15.0%, chronic productive cough from 7.3 to
6.2% and recurrent wheeze from 13.4 to 12.0%. Any
wheeze and asthmatic wheeze remained unchanged. In
contrast, the prevalence of ever asthma increased signifi-
cantly from 10.1 to 13.4%, physician-diagnosed asthma
from 9.4 to 11.6% and the use of asthma medication
from 10.9 to 12.4% (Table 3). The change in prevalence
from 1996 to 2006 expressed as odds ratios is displayed
in Figure 1. A significant decrease was found for
longstanding cough (OR 0.82, 95% 0.74-0.92), sputum
production (OR 0.80, 95% 0.72-0.87) and chronic pro-
ductive cough (OR 0.85, 95% 0.74-0.98), while physician-
diagnosed asthma increased (OR 1.28, 95% 1.14-1.44).
Table 2 Prevalence (%) of smoking habits by study year, age group and sex
Age group Sex
n All 20-29y 30-39y 40-49y 50-59y 60-69y Women Men All All¤
Smoking habits 1996
Non-smokers 3600 69.3 55.0 41.3 42.0 50.8 51.9 50.3 51.1 51.5
Ex-smokers 1511 9.3 17.9 24.9 26.5 27.8 18.6 24.1 21.5 21.1
Smokers 1932 21.4 27.1 33.7 31.5 21.3 29.4 25.5 27.4 27.4
<5 cig/day 402 7.3 7.0 5.9 5.0 3.3 5.1 6.3 5.7 5.8
5-14 cig/day 944 10.5 13.0 17.0 15.1 10.4 17.3 9.7 13.4 13.4
>14 cig/day 523 2.9 6.3 10.2 10.4 6.4 6.1 8.7 7.4 7.3
Missing data 63 0.8 0.8 0.7 1.0 1.2 0.9 0.9 0.9 0.9
Smoking habits 2006
Non-smokers 3538 75.8 74.0 56.8 45.6 48.1 55.2 61.2 58.1 59.1
Ex-smokers 1372 7.8 13.3 20.5 30.1 34.0 22.0 23.1 22.5 21.8
Smokers 1178 16.4 12.7 22.7 24.3 17.9 22.8 15.7 19.3 19.1
<5 cig/day 279 7.2 3.6 4.7 4.6 3.4 4.8 4.4 4.6 4.6
5-14 cig/day 609 6.8 6.1 11.5 13.8 9.6 13.2 6.6 10.0 9.8
>14 cig/day 237 1.7 2.5 5.5 4.9 3.8 3.9 3.9 3.9 3.8
Missing data 53 0.6 0.6 0.9 0.9 1.2 0.8 0.9 0.9 0.9
P-value* 0.003 <0.001 <0.001 <0.001 0.002 <0.001 <0.001 <0.001
All¤ = Standardized to the age and gender distribution in Norrbotten each year.
*Chi-square test of difference in prevalence of smoking habits in terms of non-smokers, ex-smokers and smokers between surveys.
Ca 1% lacks data of smoking habits each year.
Backman et al. World Allergy Organization Journal 2014, 7:1 Page 4 of 10
http://www.waojournal.org/content/7/1/1Also among subjects with physician-diagnosed asthma,
the proportion reporting symptoms common in asthma
decreased significantly from 1996 to 2006; any wheeze
from 72.1 to 63.7% (p = 0.001), recurrent wheeze from
62.2 to 51.0% (p < 0.001), asthmatic wheeze from 42.9 to
32.9% (p < 0.001) and use of asthma medication from
80.2 to 75.5% (p = 0.036).
The prevalence of physician-diagnosed asthma de-
creased with increasing age in both surveys (except in
the age group 60–69 years in 1996) (Figure 2), while
the prevalence of chronic productive cough and recur-
rent wheeze increased with increasing age. The preva-
lence of most symptoms and use of asthma medication
was higher among women than men in both surveys
(Table 3).
Respiratory symptoms and asthma in relation to smoking
Among non-smokers, ex-smokers, as well as among
smokers, the prevalence of most asthma variables in-
creased significantly from 1996 to 2006. The prevalence
of bronchitis variables did not differ between 1996 and
2006 among smokers or ex-smokers, but decreased sig-
nificantly among non-smokers. The prevalence of wheeze
variables did not differ significantly between the surveys
when stratified by smoking habits, except for an increase
in any wheeze among smokers (Table 4).From 1996 to 2006, the proportion of smokers de-
creased also among symptomatics; i.e. from 37.7 to
28.8% (p = 0.005) among subjects with chronic product-
ive cough, from 37.9 to 30.6% (p < 0.001) among subjects
with sputum production, from 34.6 to 31.0% (p = 0.151)
among subjects with longstanding cough, from 43.8 to
34.1% (p < 0.001) among subjects with recurrent wheeze,
from 37.5 to 27.7% (p = 0.001) among subjects with asth-
matic wheeze and from 24.7 to 19.9% (p = 0.035) among
subjects with physician-diagnosed asthma.
All respiratory symptoms were significantly and
strongly related to smoking in both surveys. For the
asthma variables, the highest prevalence was found
among ex-smokers (Table 4). Smoking and ex-smoking
were consistently associated with recurrent wheeze in
both surveys (Table 5). The OR:s increased with in-
creased cigarette consumption, and the highest OR:s
(>3) were found for recurrent wheeze and chronic pro-
ductive cough among those who smoked >14 cigarettes/
day. Physician-diagnosed asthma was significantly asso-
ciated with ex-smoking with an OR of 1.33 in 1996 and
1.41 in 2006.
Population attributable risk (PAR) of smoking
The PAR of smoking decreased slightly from 1996 to
2006 for all symptoms but longstanding cough. PAR was
Table 3 Prevalence (%) of respiratory symptoms and asthma by study year, age group and sex
Age group Sex
Year 20-29y 30-39y 40-49y 50-59y 60-69y P-value* Women Men P-value** All All¤ P-value***
Asthma variables
Ever asthma 1996 12.8 11.5 8.9 7.2 10.5 <0.001 10.4 9.7 0.318 10.1 10.1
2006 18.3 14.0 12.6 12.5 10.9 <0.001 14.3 12.2 0.016 13.3 13.4 <0.001
Physician-diagnosed 1996 11.8 10.1 7.7 6.8 10.7 0.016 9.4 9.3 0.899 9.3 9.4
asthma 2006 15.6 12.1 10.8 10.6 9.5 <0.001 12.4 10.5 0.020 11.5 11.6 <0.001
Asthma medication 1996 11.8 11.8 9.5 10.0 11.7 0.395 12.2 9.7 0.001 10.9 10.9
2006 14.1 11.9 11.7 12.6 12.0 0.315 13.7 11.0 0.001 12.4 12.4 0.009
Bronchitis variables
Longstanding cough 1996 13.0 12.0 12.0 11.9 13.3 0.883 13.6 11.2 0.002 12.4 12.4
2006 10.6 9.0 9.1 11.1 10.7 0.334 11.0 9.2 0.017 10.1 10.1 <0.001
Sputum production 1996 19.9 19.4 15.8 19.1 22.0 0.296 19.0 19.2 0.830 19.1 19.0
2006 18.6 14.1 12.2 15.4 15.4 0.288 14.7 15.2 0.551 15.0 15.0 <0.001
Chronic productive 1996 4.9 5.9 5.7 9.3 11.9 <0.001 7.1 7.8 0.260 7.4 7.3
cough 2006 6.1 5.1 5.5 6.8 7.7 0.017 5.3 7.3 0.001 6.3 6.2 0.009
Wheeze variables
Any wheeze 1996 18.4 19.1 16.5 19.0 20.3 0.295 19.6 17.6 0.030 18.6 18.5
2006 20.8 17.7 17.5 19.7 17.6 0.317 19.0 18.2 0.423 18.6 18.6 0.974
Recurrent wheeze 1996 12.1 13.6 12.2 13.8 15.6 0.021 14.1 12.8 0.119 13.4 13.4
2006 10.3 11.1 11.8 13.8 12.3 0.030 11.9 12.2 0.765 12.1 12.0 0.019
Asthmatic wheeze 1996 7.8 7.8 6.3 8.1 9.6 0.117 7.6 8.1 0.446 7.9 7.8
2006 8.3 5.8 7.3 8.2 7.1 0.857 7.6 7.2 0.519 7.4 7.4 0.305
All¤ = Standardized to the age and gender distribution in Norrbotten each year.
*Test for trend by age group.
**Chi-square test of difference in prevalence by sex.
***Chi-square test of difference in prevalence by year of study (among All).
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18.3% in 2006), and ranged from 9.8% to 14.1% for the
bronchitis symptoms. PAR of smoking was not signifi-
cant for physician-diagnosed asthma (Figure 3). In both
surveys, adjusted PAR tended to be higher than PAR.
Adjusted PAR was highest for recurrent wheeze (25.5%
in 1996, 20.6% in 2006), and ranged from 10.9% to
18.0% for the bronchitis symptoms.
Discussion
The main result of our study is the decrease in preva-
lence of most respiratory symptoms, particularly symp-
toms of bronchitis, from 1996 to 2006. This decrease
parallels a 30% decrease in smoking prevalence, a de-
crease which was significant in all age groups, in both
sexes, and in the proportion of smokers consuming >14
cigarettes/day. All respiratory symptoms were associated
with smoking, and the proportion of respiratory symp-
toms attributed to smoking (PAR of smoking) varied
from 10 to 25%. The decrease in smoking prevalence
was greater than the decrease in prevalence of symp-
toms, and a tendency of a decrease in PAR of smokingfrom 1996 to 2006 was observed for most respiratory
symptoms. In contrast to respiratory symptoms, the
prevalence of physician-diagnosed asthma increased and
asthma was not consistently associated with smoking.
It is of great importance for preventive decisions to iden-
tify effects of changes in smoking habits on respiratory
health in the population. In 2005, legislation was imple-
mented in Sweden to reduce smoking in restaurants, which
probably contributed to the decrease in smoking. More
women than men smoked already in 1996, and the decrease
in smoking prevalence was more pronounced among men
compared to women. Thus, the gender difference in smok-
ing prevalence increased. Worryingly, a recent study indi-
cates an increase in prevalence of smoking and symptoms
of bronchitis among teen-age girls in Sweden [31]. It is of
great importance to establish a decrease in cigarette con-
sumption also among women; in particular since women
are more susceptible to cigarette smoke than men [32].
Few studies have reported PAR of smoking for re-
spiratory symptoms and asthma. Our results imply
that if smoking had been eliminated, 10-25% of the








Adjusted Odds Ratios for study year 2006 (vs 1996)
Figure 1 Changes in asthma and respiratory symptom
prevalence from 1996 to 2006. Legend: The changes in
physician-diagnosed asthma and respiratory symptom prevalence
from 1996 to 2006 are expressed as Odds Ratios with corresponding
95% Confidence Intervals for 2006 as survey year (1996 as reference)
from logistic regression models adjusted for age group, sex, family
history of asthma and smoking habits.
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the Global Allergy and Asthma European Network
(GA2LEN) study performed in 2008 with the Swedish
part of the European Community Respiratory Health
Survey (ECHRS) from 1990 [5] also found a decrease in
the prevalence of smoking, and a decrease in PAR of
smoking for any wheeze. However, the methods for es-
timating PAR differed somewhat between the present
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Figure 2 Prevalence (%) of physician-diagnosed asthma by age
group and study year.Comparisons of prevalence estimates between studies
are difficult, since populations, questionnaires, and clas-
sification of symptoms and diseases often differ. One
major advantage of our study is the use of identical
methods in both surveys. The same methods as in our
study were used in Helsinki, Finland, and that study also
found a decrease in symptoms of bronchitis parallel to a
decrease in smoking prevalence from 1996 to 2006 [21].
In west Sweden, a decrease was seen in the prevalence
of most respiratory symptoms from 1990 to 2008 paral-
lel to a 50% decrease in smoking prevalence [6]. In con-
trast to our results and the studies cited above, a study
in Stockholm using identical methods found the preva-
lence of symptoms to be more or less level from 1996
to 2006, despite a decrease in smoking prevalence by
43% [22].
The decrease in the prevalence of bronchitis symp-
toms is probably mainly a result of the decrease in
smoking prevalence, but also of some other factor since
we found a decrease among non-smokers. The decrease
among non-smokers could be related to a reduction of
environmental tobacco smoke (ETS), which followed the
stricter Swedish smoking legislation. The increase in use
of asthma medication, which can be prescribed also for
bronchitis symptoms, may also contribute to a decrease
in symptoms.
Wheeze is a common symptom both in asthma and
bronchitis and is strongly related to smoking [6,22,25].
In contrast to bronchitis symptoms, the prevalence of
any wheeze and asthmatic wheeze remained at a similar
level in 2006 compared to 1996, also stratified by smok-
ing habits, while recurrent wheeze decreased slightly but
significantly. Since PAR of smoking was largest for re-
current wheeze, with smoking explaining about one fifth
of the symptom prevalence, a decrease in the prevalence
of recurrent wheeze was expected due to the decrease in
smoking prevalence. Actually, a pronounced decrease in
the prevalence of all wheeze symptoms was expected
due to the decrease in smoking prevalence. One hypoth-
esis that would explain the lack of an overall decrease in
wheeze symptoms is that a parallel increase in asthma
prevalence levels the prevalence of wheeze. Smoking has
some anti-inflammatory effects and may be inversely re-
lated to allergic sensitisation [33,34]. Regarding asthma
however, there is no data indicating a similar effect of
smoking. Instead several studies suggest no effect or an
increased risk of smoking on the incidence of asthma
among adults [8-11]. Further, parental smoking increases
the risk for childhood asthma [35,36]. Thus, it is not
likely that the increase in asthma is related to the de-
crease in smoking.
Compared to similar studies from other countries
[13,14,37] as well as in other Swedish studies using the
same questionnaire as in our study [6,21,28], a higher
Table 4 Prevalence (%) of respiratory symptoms and asthma by study year and smoking habits
Non-smokers Ex-smokers Smokers
Year % Diff by year % Diff by year % Diff by year Diff by smoking
P-value P-value P-value P-value
Asthma variables
Ever asthma 1996 9.9 11.1 9.4 0.257
2006 12.3 0.002 15.0 0.002 14.3 <0.001 0.021
Physician-diagnosed 1996 9.0 11.0 8.3 0.023
asthma 2006 10.6 0.023 12.0 0.053 11.8 0.001 0.026
Asthma medication 1996 10.7 12.0 10.5 0.322
2006 11.2 0.453 14.8 0.026 12.7 0.058 0.003
Bronchitis variables
Longstanding cough 1996 11.7 10.0 15.6 <0.001
2006 7.8 <0.001 10.8 0.485 16.1 0.712 <0.001
Sputum production 1996 16.1 16.9 26.3 <0.001
2006 12.1 <0.001 14.9 0.157 23.7 0.098 <0.001
Chronic productive cough 1996 6.4 6.4 10.2 <0.001
2006 5.1 0.027 6.6 0.879 9.3 0.436 <0.001
Wheeze variables
Any wheeze 1996 14.4 17.0 27.6 <0.001
2006 14.2 0.836 19.0 0.175 31.2 0.029 <0.001
Recurrent wheeze 1996 9.5 12.4 21.4 <0.001
2006 8.6 0.156 13.0 0.668 21.1 0.848 <0.001
Asthmatic wheeze 1996 6.1 8.5 10.8 <0.001
2006 5.7 0.469 9.0 0.591 10.5 0.834 <0.001
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finding confirms previous indications of a north–south
gradient in asthma prevalence in Sweden [38,39]. The
prevalence of physician-diagnosed asthma increased from
1996 to 2006, also when stratified by smoking. The highest
prevalence of asthma was found among ex-smokers, a
result confirming other cross-sectional studies [6,12].
It is known that diagnosis of COPD significantly impacts
smokers to quit smoking [40] and therefore it could be
suggested that smokers who get an asthma diagnosis
also are likely to quit smoking, as several studies have
found an association between current smoking and in-
cident asthma [8,10,11]. The prevalence of physician-
diagnosed asthma decreased by age in both surveys, in
line with results from other studies [6,22]. In 1996
however, in contrast to 2006, there was a higher preva-
lence of asthma in the oldest age group (60–69 years)
compared to those aged 30–59 years. This result might
reflect misclassification of COPD as asthma among the
elderly in 1996.
Does the estimated increase in the prevalence of
asthma reflect a “true” increase in asthma? The propor-
tion reporting symptoms common in asthma decreased
significantly from 1996 to 2006 among subjects withphysician-diagnosed asthma. This decrease occurred
despite the fact that the proportion of subjects using
asthma medicines also decreased significantly among the
asthmatics. These data suggest an increased awareness
of asthma in the society, improved recognition of asthma
in primary care and an increasing diagnostic activity, in
particular of mild asthma, which probably have contrib-
uted to the observed increase in physician-diagnosed
asthma; a result in line with studies in other areas
[6,21,22]. On the other hand, the lack of decrease in
asthmatic wheeze and any wheeze despite the major de-
crease in smoking prevalence may indicate a true in-
crease in asthma in Northern Sweden. Also, both
asthma and use of asthma medication increased most in
the youngest age group, which imply a true increase of
asthma since misclassification of asthma as e.g. COPD is
unlikely among young subjects. One might argue that
the observed increase in asthma could be due to both a
true increase in asthma as well as an increased diagnos-
tic activity, which would be a result in line with studies
from other countries [41]. This hypothesis requires fur-
ther studies including clinical examinations. In our
study, the majority of subjects with physician-diagnosed
asthma used asthma medicines in both surveys, although
Table 5 Risk factor analysis: Odds Ratios with 95% Confidence Intervals from logistic regression models
Dependent variables













Independent variables OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI
Age 20-29 years 1 1 1 1 1 1
30-39 years 1.14 (0.82-1.60) 0.87 (0.59-1.28) 0.82 (0.65-1.05) 0.78 (0.60-1.01) 1.04 (0.83-1.31) 1.18 (0.88-1.58)
40-49 years 1.01 (0.73-1.42) 0.85 (0.59-1.22) 0.60 (0.46-0.77) 0.64 (0.50-0.83) 0.82 (0.65-1.04) 1.07 (0.81-1.41)
50-59 years 1.80 (1.32-2.47) 1.07 (0.76-1.52) 0.55 (0.42-0.72) 0.62 (0.48-0.80) 1.03 (0.81-1.29) 1.25 (0.96-1.64)
60-69 years 2.59 (1.90-3.53) 1.35 (0.95-1.92) 0.89 (0.69-1.15) 0.60 (0.46-0.79) 1.31 (1.04-1.65) 1.23 (0.93-1.63)
Sex Female 1 1 1 1 1 1
Male 1.17 (0.98-1.41) 1.55 (1.25-1.92) 1.05 (0.89-1.24) 0.90 (0.77-1.06) 0.98 (0.85-1.13) 1.19 (1.01-1.39)
Family history
of asthma
No/Don’t know 1 1 1 1 1 1
Yes 1.81 (1.49-2.21) 2.37 (1.91-2.95) 3.26 (2.76-3.85) 3.39 (2.88-4.00) 2.41 (2.07-2.79) 2.71 (2.30-3.20)
Smoking habits Non-smokers 1 1 1 1 1 1
Ex-smokers 0.89 (0.69-1.14) 1.17 (0.89-1.54) 1.33 (1.09-1.64) 1.41 (1.15-1.72) 1.34 (1.10-1.62) 1.50 (1.22-1.85)
<5 cig/day 0.60 (0.35-1.02) 1.41 (0.87-2.28) 1.01 (0.70-1.46) 1.09 (0.74-1.61) 1.70 (1.26-2.30) 2.18 (1.55-3.06)
5-14 cig/day 1.43 (1.09-1.86) 1.61 (1.14-2.27) 0.85 (0.65-1.12) 1.33 (1.01-1.74) 2.61 (2.14-3.17) 3.09 (2.45-3.91)
>14 cig/day 3.07 (2.35-4.02) 3.31 (2.23-4.91) 0.95 (0.67-1.34) 0.68 (0.41-1.14) 3.49 (2.77-4.40) 3.32 (2.39-4.63)
Statistically significant Odds Ratios (OR) with corresponding 95% Confidence Intervals (CI) are bolded.
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http://www.waojournal.org/content/7/1/1somewhat less so in 2006 compared to 1996. In a study
from Australia the authors argue that improved guide-
lines on how to implement asthma treatment are re-
quired [42], but as we cannot provide detailed









Figure 3 Population attributable risks (PAR in % with corresponding
asthma and respiratory symptoms in 1996 and 2006, respectively.cannot evaluate if the adherence to maintenance treat-
ment is appropriate.
The validity and reliability of the present study was
high due to the population-based samples, the high par-




95% Confidence Intervals) of smoking for physician-diagnosed
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http://www.waojournal.org/content/7/1/1questionnaire. The somewhat lower participation rate in
2006 compared to 1996 could possibly lead to a slight
overestimation of symptom prevalence in 2006 [43].
An overestimation in 2006 would not alter the findings
of decreased prevalence in symptoms, but could pos-
sibly affect the observed increase in asthma prevalence.
However, the close to identical prevalence estimates
after adjustment to the age and gender distribution in
Norrbotten each year verify the representativeness of
the study sample. A weakness is the lack of clinical
data when discussing asthma, and measures of cotinine
for validating data about smoking. Further, data of
exposure to ETS, body weight, gastro-oesophageal reflux,
obstructive sleep apnoea and occupational dust exposure
would have been valuable, since the presence of these fac-
tors may have changed between surveys, which in turn
could have contributed to a change in both respiratory
symptom and asthma prevalence. The cross-sectional study
design weakens the discussion of causality. However, the
strong and consistent association between smoking and
respiratory symptoms in both surveys as well as the de-
crease of both smoking and bronchitis symptoms imply
an improvement in respiratory health in the population at
least partly due to the decrease in smoking.
Conclusions
In conclusion, we found that respiratory symptoms, in par-
ticular bronchitis symptoms, decreased parallel to a de-
crease in smoking over a 10-year period from 1996 to 2006.
In contrast, the prevalence of physician-diagnosed asthma
increased during the same period. The hypothesis that the
observed increase in asthma reflects a “true” increase in
asthma prevalence has to be confirmed by clinical studies.
Additionally, up to one fourth of the respiratory symptom
prevalence in the population was attributable to smoking.
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